1. Home
  2. MSEX vs CRVS Comparison

MSEX vs CRVS Comparison

Compare MSEX & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Middlesex Water Company

MSEX

Middlesex Water Company

HOLD

Current Price

$57.66

Market Cap

984.5M

Sector

Utilities

ML Signal

HOLD

Logo Corvus Pharmaceuticals Inc.

CRVS

Corvus Pharmaceuticals Inc.

HOLD

Current Price

$14.98

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MSEX
CRVS
Founded
1897
2014
Country
United States
United States
Employees
395
N/A
Industry
Water Supply
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
984.5M
1.1B
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
MSEX
CRVS
Price
$57.66
$14.98
Analyst Decision
Buy
Strong Buy
Analyst Count
3
6
Target Price
$61.33
$30.17
AVG Volume (30 Days)
153.9K
1.3M
Earning Date
04-30-2026
05-07-2026
Dividend Yield
2.77%
N/A
EPS Growth
N/A
48.04
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$10.60
N/A
Revenue Next Year
$10.94
N/A
P/E Ratio
$22.68
N/A
Revenue Growth
N/A
N/A
52 Week Low
$44.94
$3.79
52 Week High
$62.18
$26.95

Technical Indicators

Market Signals
Indicator
MSEX
CRVS
Relative Strength Index (RSI) 73.53 69.99
Support Level $49.91 $14.24
Resistance Level $62.18 $16.85
Average True Range (ATR) 1.20 0.79
MACD 0.47 0.43
Stochastic Oscillator 93.28 79.70

Price Performance

Historical Comparison
MSEX
CRVS

About MSEX Middlesex Water Company

Middlesex Water Co owns and operates regulated water utility and wastewater systems in the U.S. The company has two operating segments, Regulated and Non-Regulated. The regulated business includes collecting and distributing water to residential, commercial, industrial, and fire protection consumers. The non-regulated business includes contract services for the operation of private water and wastewater systems. The majority of the company's revenue is derived from the Regulated segment and from residential customers.

About CRVS Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.

Share on Social Networks: